A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".
Saved in:
| Title: | A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". |
|---|---|
| Authors: | Ständer, Sonja1 (AUTHOR), Pinter, Andreas2 (AUTHOR), Hougeir, Firas G.3 (AUTHOR), Guyot, Patricia4 (AUTHOR), Xu, Yingxin5 (AUTHOR), Praestgaard, Amy H.6 (AUTHOR), Freemantle, Nick7 (AUTHOR), Rossi, Ana B.6 (AUTHOR), Bégo‑Le‑Bagousse, Gaëlle4 (AUTHOR), Wang, Zhixiao5 (AUTHOR), Noonan, Kerry6 (AUTHOR), Bastian, Mike8 (AUTHOR) mike.bastian@sanofi.com |
| Source: | Dermatology & Therapy. Feb2026, Vol. 16 Issue 2, p1433-1437. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938210 |
|---|---|
| DOI: | 10.1007/s13555-025-01627-4 |
